September 2002: Established in Shanghai, China
Support and capital from Hutchison Whampoa Limited (now CK Hutchison)
Initiated botanical drug R&D programs
April 2005: Initiated new chemical entity (NCE) drug discovery program
May 2005:  Filed first Investigational New Drug (IND) application with the US Food & Drug Administration (US FDA)
May 2006: Parent company Hutchison China MediTech Limited (Chi-Med) successfully completed its initial public offering on London’s Alternative Investment Market (AIM)
November 2006: Initiated oncology collaboration with Merck AG
September 2007: Initiated first collaboration with Eli Lilly
December 2008: Initiated immunology collaboration with Johnson & Johnson
October 2009: First NCE entered phase I clinical trial in Australia
November 2009: Successfully completed HMPL-004 global Phase II clinical trial for ulcerative colitis
May 2010: HMPL-004 Distinguished Plenary Presentation at Digestive Disease Week
Sulfatinib received SFDA Green Channel approval and begins Phase I clinical trial in China
November 2010: Received venture capital investment
January 2011:  Fruquinitinib entered first-in-human Phase I clinical trial in China
November 2011:  Epitinib initiated first-in-human Phase I clinical trial in China
December 2011: AstraZeneca and Hutchison Medi Pharma Entered into Global Collaboration to Co-Develop and Commercialize Novel Cancer Therapy
March 2012: HMP initiated Phase I clinical study of its novel c-Met inhibitor Savolitinib
November 2012: HMP initiated Phase I clinical study with novel EGFR inhibitor Theliatinib
November 2012: HMP established joint venture with Nestlé Health Science
October 2013: Cancer Therapy Collaboration with Lilly
July 2015:  VC exchanged shares in HMP for shares in Chi-Med
March 2016:  Chi-Med successfully completed its additional public offering on NASDAQ